The following are Industry Sponsored Clinical Research (ISR) currently conducted at the various centres. For further information, please contact the Principal Investigator.
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Abdominal & Pelvic | Hyperthermia in Treating Patients with Painful Unresectable Abdominal or Pelvic Malignancy | ADIPOLAB-001 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) |
N/A |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Bladder Cancer | A Phase 3, Randomized, Open-Label Study to Evaluavate Perioperative Enfortumab Vedotin plus Pembrolizumab (MK-3475) versus Neodjuvant gemcitabine and cisplatin in cisplatin-eligible participants with muscle-invasive bladder cancer (KEYNOTE-B15/EV-304) | KEYNOTE B15 | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE |
| Bladder Cancer | A Randomized phase 3 study evaluating cystectomy with perioperative pembrolizumab and cystectomy with perioperative enfortumab vedotin and pembrolizumab versus cystectomy alone in cisplatin-ineligible participants with muscle-invasive bladder cancer | KEYNOTE 905 | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE |
| Muscle-invasive bladder cancer | A phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC) | KEYNOTE 992 | Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext. 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE |
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE | |||
| Sunway Medical Centre | Dr Nik Muhd Aslan | +603 – 74919191/ 603-8601 1079 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Breast Cancer | Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients with APOBEC3B | AUROR | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) |
CLICK HERE |
| Triple Negative Breast Cancer | A Phase III Double-blind Randomised Study Assesing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) | CAPITELLO-290 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 014 – 9337966 (Kimee Ku) |
CLICK HERE |
| Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE | |||
| Breast Cancer | Studies of Epigenetic changes in blood samples in breast cancer patients | EPIGENECTIC | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 012 301 0042 (Alice) |
N/A |
| HER2+ Breast Cancer | A Two-part, Phase III, Multicenter, Randomized (1:1), Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients with HER2-Positive Advanced Breast Cancer with a PIK3CA Mutation | EPIK-B2 | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICKH HERE |
| University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 014 – 9337966 (Kimee Ku) |
CLICK HERE | |||
| Metastatic or Advanced Triple Negative Breast Cancer | A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation | EPIK-B3 | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR ADLINDA ALIP | 010 – 4346150 (Suganiya) |
CLICK HERE | |||
| Beacon Hospital Sdn Bhd | Dato’ Dr Mohamed Ibrahim A Wahid | +603 – 7806 0845 | CLICK HERE | |||
| Breast Cancer | Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer | EXEMASTANE | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) |
CLICK HERE |
| Breast Cancer | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer | KEYNOTE B49 | University of Malaya Medical Centre (UMMC) | DR NUR FADHLINA ABDUL SATAR | 014 – 9337966 (Kimee Ku) |
CLICK HERE |
| HR+, HER2- | Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes In Advanced Brest Cancer in Asia | MADELINE | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
N//A |
| Metastatic breast cancer | A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer | RIGHT CHOICE | Kuala Lumpur Hospital (HKL) | DR MALWINDER SINGH SANDHU | +603 – 2615 5555, Ext. 1782 / 1783 |
CLICK HERE |
| Sarawak General Hospital | DR VOON PEI JYE | +608 – 2276 820 | CLICK HERE | |||
| Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE | |||
| Hospital Wanita dan Kanak-Kanak Sabah | DR FLORA CHONG LI TZE | +608 – 8522 600, Ext. 2272 | CLICK HERE | |||
| Breast Cancer | A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | SERENA-4 | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI | +603 – 2296 0800 | CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 014 – 9337966 (Kimee Ku) 010 236 1109 (Wei Ying) |
CLICK HERE | |||
| Breast Cancer | Phase II Study to assess the efficacy of Talazoparib in asian mEtastatic breast caNcer patients with a hOmologous Recombinant deficiency (HRD) signature (TENOR) | TENOR | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 010 236 1109 (Wei Ying) |
N/A |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Metastatic adenocarcinoma and squamous cell carcinoma of the esophagus | A phase III randomized open-label study of single agent pembrolizumab vs physicians’ choice of single agent docetaxel, paclitaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus that have progressed after first-line standard therapy (KEYNOTE-181) | MK3475-181 | Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Gastrointestinal Cancers | Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers | ASCOLT | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 014 – 9337966 (Kimee Ku) 012 301 0042 (Alice) |
CLICK HERE |
| Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | GLOW | Kuala Lumpur Hospital (HKL) | DR NOOR ZAFIFAH BINTI ZAKARIA | +603 – 2615 5555, Ext. 1620 / 1144 |
CLICK HERE |
| Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE | |||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE | |||
| Hospital Wanita dan Kanak-Kanak Sabah | DR SUCHARIT PONGPRAKYUN | +608 – 8522 600, Ext. 2272 | CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 010 236 1109 (Wei Ying) |
CLICK HERE | |||
| Gastrointestinal Cancers | A Phase 3 Double-blinded, two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Perticipants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation | KEYNOTE 937 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 012 301 0042 (Alice) |
CLICK HERE |
| Gastrointestinal Cancers | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma | KEYNOTE 966 | University of Malaya Medical Centre (UMMC) | DR WAN ZAMANIAH | 010 – 4346150 (Suganiya) |
CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Head & Neck Cancer | The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN). |
KURA | University of Malaya Medical Centre (UMMC) | DR NUR FADHLINA ABDUL SATAR | 014 – 9337966 (Kimee Ku) |
CLICK HERE |
| Head and Neck Squamous Cell Carcinoma | The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) | KO-TIP-007 | National Cancer Institute (IKN) | DR SUHANA BINTI YUSAK | +603 – 88925555, Ext. 4168 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Non-small cell lung cancer | A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) | CANOPY A | Pantai Hospital Kuala Lumpur | DR MASTURA BINTI MD YUSOF | +603 – 2296 0764 / 0800 |
CLICK HERE |
| Hepatocellular Carcinoma | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) | KEYNOTE-937 | National Cancer Institute (IKN) | DR WONG YOKE FUI, Florence | +603 – 8892 5555, Ext. 4168 | CLICK HERE |
| Sarawak General Hospital | DR LIM YUEH NI | +608 – 2276 820 | CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Non-small cell lung cancer | A Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer | ARC-10 | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI | +603 – 2296 0800 | CLICK HERE |
| Universiti Kebangsaan Malaysian Medical Centre (UKMMC) | PROF DATO’ DR FUAD ISMAIL | +603 – 9145 5664 (SC) | N/A | |||
| Non-small cell lung cancer | Real-World Utilization and Outcomes with Dacomitinib First-Line Treatment for EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer among Asian Patients – A Multi-Center Chart Review |
ARIA | Pantai Hospital Kuala Lumpur | DR JOHN LOW SENG HOOI | +603 – 2296 0800 | CLICK HERE |
| Lung Cancer | Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer | ARTOG-OO4 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) |
CLICK HERE |
| Lung Cancer (NSCLC) | A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study). | ATORG001 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) 010 236 1109 (Wei Ying) |
CLICK HERE |
| Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | +603 – 7786 0845 | CLICK HERE | |||
| Advanced or Metastatic NSCLC | A single-arm, open-label, phase 2 study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (egfr) activation mutation | ATORG003 | Beacon Hospital Sdn Bhd | Dr Tho Lye Mun | +603 – 7786 0845 | CLICK HERE |
| Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | +603 – 7786 0845 | CLICK HERE | |||
| Sarawak General Hospital | DR LIM YUEH NI | +608 – 2276 820 | CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 017 268 0664 (Yok Yong) |
CLICK HERE | |||
| Non-small cell lung cancer | A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) | CANOPY A | Pulau Pinang Hospital | DR TAN AI LIAN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE |
| Sarawak General Hospital | DR SYADWA BINTI ABDUL SHUKOR | +608 – 2276 820 | CLICK HERE | |||
| Non-small Cell Lung Cancer | A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK301) in Combination with Platinum+Pemetrexed Chemotherapy in Subjects with First-Line Metastatic Non- squamous Non-Small Cell Lung Cancer [Protocol No. CK-301 301] | CHECKPOINT | Universiti Kebangsaan Malaysian Medical Centre (UKMMC) | PROF DATO’ DR FUAD ISMAIL | +603 – 9145 5664 (SC) | N/A |
| Lung Cancer | Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients – A Multi Center Chart Review | DACOMITINIB | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 010 236 1109 (Wei Ying) |
CLICK HERE |
| Non-small Cell Lung Cancer | A Two Part Randomized Phase 3 Study of Combination of Cemiplimab (Anti-PDA-1 Antibody) and Platinum Based Doublet Chemotherapy in First Line Treatment of Patients with Advanced o Metastatic Non Small Cell Lung Cancer |
EMPOWER | Universiti Kebangsaan Malaysian Medical Centre (UKMMC) | PROF DATO’ DR FUAD ISMAIL | +603 – 9145 5664 (SC) | N/A |
| Advanced or Metastatic NSCLC | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study) | INSIGHT-2 | Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | +603 – 7786 0845 | CLICK HERE |
| Sunway Medical Centre | Dr Lim Boon Khaw | +603 – 74919191/ 603-8601 1079 | CLICK HERE | |||
| Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer | A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304) | INCMGA 0012-304 | Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | +603 -7786 0845 | CLICK HERE |
| Tengku Ampuan Afzan Hospital, Kuantan | DR AISHAH BINTI IBRAHIM | +609 – 5572 922 | CLICK HERE | |||
| Sarawak General Hospital | DR AIDEN HENG FOOK YEW | +608 – 2276 820 | CLICK HERE | |||
| Non-Small Cell Lung Cancer (Stage III) | Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA) | LAURA | Kuala Lumpur Hospital (HKL) | DR IBTISAM MUHAMAD NOR | +603 – 2615 5555, Ext. 1620 / 1144 |
CLICK HERE |
| University of Malaya Medical Centre (UMMC) | DR ADLINDA ALIP | 014 – 9337966 (Kimee Ku) |
CLICK HERE | |||
| Beacon Hospital Sdn Bhd | Dato’ Dr Mohamed Ibrahim A Wahid | +603 – 7786 0845 | CLICK HERE | |||
| Non-small Cell Lung Cancer | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/ Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671) | MK-3475-671 | Sarawak General Hospital | DR AIDEN HENG FOOK YEW | +608 – 2276 820 | CLICK HERE |
| Advanced or Metastatic NSCLC | A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine | ML41262 | Beacon Hospital Sdn Bhd | Dr Tho Lye Mun | +603 – 7786 0845 | N/A |
| Non-Small Cell Lung Cancer | A phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy | MS200095-0031 | Tengku Ampuan Afzan Hospital, Kuantan | PROF DR HOW SOON HIN | +609 – 5572 922 | CLICK HERE |
| Pantai Hospital Kuala Lumpur | DR THO LYE MUN | +603 – 2296 0800 | CLICK HERE | |||
| Sarawak General Hospital | DR SYADWA BINTI ABDUL SHUKOR | +608 – 2276 820 | CLICK HERE | |||
| Pulau Pinang Hospital | DR IRFHAN ALI B HYDER ALI | +604 – 2225 767 / 2225 762 / 2225 766 |
CLICK HERE | |||
| Metastatic Non-Small Cell Lung Cancer | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) | Mariposa | Tengku Ampuan Afzan Hospital, Kuantan | PROF DR HOW SOON HIN | +609 – 5572 922 | CLICK HERE |
| Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE | |||
| Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE | |||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE | |||
| Beacon Hospital Sdn Bhd | Dr Azura Rozila Ahmad | +603 – 7786 0845 | CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR ADLINDA ALIP | 010 – 4346150 (Suganiya) |
CLICK HERE | |||
| Metastatic Non-Small Cell Lung Cancer | A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Papillon | Sultan Ismail Hospital, Johor Bahru | DR LIM CHUN SEN | +607 – 3565 155 | CLICK HERE |
| Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext. 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE | |||
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR ADLINDA ALIP | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE | |||
| Advanced NSCLC | Real-world utilization and outcomes with “study drug” first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi-center chart review | PFIZER A7471067 | Beacon Hospital Sdn Bhd | Dr Tho Lye Mun | +603 – 7786 0845 | CLICK HERE |
| Recurrent or Metastatic Non-squamous Non-small Cell Lung Cancer | A Randomized, Double-blind, Parallel group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer | SAMSON II | Sunway Medical Centre | Dr Nik Muhd Aslan | +603 – 74919191/ 603-8601 1079 | CLICK HERE |
| Non-small Cell Lung Cancer | A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer | STELLA | Universiti Kebangsaan Malaysian Medical Centre (UKMMC) | PROF DATO’ DR FUAD ISMAIL | +603 – 9145 5664 (SC) | N/A |
| Lung Cancer | A phase 3 study to evaluate zimberelimab (AB122) monotherapy compared to standard chemotherapy of zimberelimab combined with AB154 in front-line, PDL1-Positive, locally advanced or metastatic non-small cell lung cancer | ZIMBERELIMAB | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 012 301 0042 (Alice) |
CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Ovarian Cancer | A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer | EPIK-O | University of Malaya Medical Centre (UMMC) | DR ROZITA ABDUL MALIK | 017 268 0664 (Yok Yong) |
CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Metastatic Prostate Cancer | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer | 64091742PCR0002 | Sarawak General Hospital | DR HADI BIN AB.JALIL | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 / 276 820 |
CLICK HERE |
| Pulau Pinang Hospital | DR SOO HOO HWOEI FEN | +604 – 2225 767 / 2225 762 / 2225 766 / 2225 586 |
CLICK HERE | |||
| Kuala Lumpur Hospital (HKL) | DR MUTHUKKUMARAN A/L THIAGARAJAN | +603 – 2615 5555, Ext. 1782 / 1783 / +60 17-233 6295 (Amirah) |
CLICK HERE | |||
| Metastatic Castration-Sensitive Prostate Cancer | Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | AMPLITUDE | Kuala Lumpur Hospital (HKL) | DR PRATHEPAMALAR A/P YEHGAMBARAM | +603 – 2615 5555, Ext. 1620 / 1144 |
CLICK HERE |
| Sarawak General Hospital | DR HADI BIN AB.JALIL | +608 – 227 6666 / 6035 / 276 820 |
CLICK HERE | |||
| National Cancer Institute (IKN) | DR ARNIL GEORGE SIRIMANNE | +603 – 8892 5555, Ext. 4168 | CLICK HERE | |||
| Pulau Pinang Hospital | DR FONG CHIN HENG | +604 – 2225 767 / 2225 762 / 2225 766 |
CLICK HERE | |||
| University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE | |||
| Metastic Prostate Cancer | Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer | MAGNITUDE | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE |
| Hospital Wanita dan Kanak-Kanak Sabah | Dr Flora Chong Li Tze | +6088-522600, Ext. 2272 | CLICK HERE | |||
| Prostate Cancer | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer | PREVALENCE | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE |
| Prostate Cancer | A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients WithNonmetastatic Castration- Resistant Prostate Cancer | PROSPER | Universiti Kebangsaan Malaysian Medical Centre (UKMMC) | PROF DATO’ DR FUAD ISMAIL | +603 – 9145 5664 (SC) | N/A |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Renal Cancer | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) |
MK6482-012 | University of Malaya Medical Centre (UMMC) | DR MARNIZA SAAD | +6012 – 672 8761 (Cryst Sari – CS) |
CLICK HERE |
| TYPE | TITLE | SHORT TITLE | SITE | PRINCIPAL INVESTIGATOR | CONTACT | LINKS |
| Sarcoma/Solid Tumor Malignacies | Immune Modulatory Effect of Hyperthermia During Treatment of Recurrent or Metastatic Solid Organ Malignancies | ADIPOLAB-002 | University of Malaya Medical Centre (UMMC) | DR HO GWO FUANG | 014 – 9337966 (Kimee Ku) 010 236 1109 (Wei Ying) |
N/A |
The information above was last updated on 19 August 2021.
Source: http://clinicalresearch.my/
Links are from CLINICALTRIAL.GOV
